Q2FY16 Results declared
BSE Results link
Revenue Growth 13%
EBITDA Growth 25% (Margin 21.61% vs 19.44%)
PBT Growth 31%
PAT Growth 30% (excluding exceptional item)
- Exceptional loss of 2.42cr reported, dragging reported PAT down to 20cr
Overall looks good set of numbers, considering that we are not expecting any fireworks until US FDA approval and revenue growth thereafter.
Mr. Bhutada had already clarified after Q4FY15 results that all the ongoing initiatives will drive revenue growth by 2016 end or 2017. Until then 5-10% growth guidance was provided. They have done better than the near term guidance at least.
However, brokers have a different set of expectations.(FY16 growth: IndiaNivesh 24.5%, Karvy 23.5%)
| Subscribe To Our Free Newsletter |
